Bachem (BCHMF) to Release Quarterly Earnings on Thursday

Bachem (OTCMKTS:BCHMF) is projected to issue its results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of $1.11 per share and revenue of $466.9280 million for the quarter.

Bachem Stock Performance

Bachem stock opened at $76.77 on Thursday. The stock’s fifty day moving average price is $74.37 and its two-hundred day moving average price is $68.20. Bachem has a one year low of $60.51 and a one year high of $82.73.

Wall Street Analyst Weigh In

BCHMF has been the subject of a number of analyst reports. UBS Group raised Bachem to a “buy” rating in a research note on Tuesday, December 2nd. Royal Bank Of Canada reissued an “outperform” rating on shares of Bachem in a report on Monday, January 26th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

Bachem Company Profile

Bachem Holding AG is a Switzerland‐based specialty biochemical company focused on the development, manufacturing and commercialization of peptides and oligonucleotides. Serving pharmaceutical and biotechnology clients as well as academic research institutions, the company offers a broad spectrum of products ranging from custom peptide synthesis for research applications to clinical and commercial‐grade active pharmaceutical ingredients (APIs). Bachem’s expertise extends to process development, scale‐up and GMP‐compliant production, supporting projects in therapeutic areas such as oncology, metabolic disorders and infectious diseases.

Founded in 1971 and headquartered in Bubendorf, Switzerland, Bachem has grown through strategic investments in production capacity and the acquisition of complementary peptide and oligonucleotide technologies.